Data from a late-stage study for testin if AstraZeneca’s diabetes drug Farxiga could treat patients, who were diagnosed with COVID-19 and at risk of developing serious symptoms showed signs of failure, the drugmaker said on Monday.
The Farxiga data did not attain statistical significance in bringing down any chances of the disease getting worsened and death in such patients, said the Anglo-Swedish drugmaker.
In the Farxiga study, the drug was given over 30 days in a global trial of 1,250 patients hospitalised with COVID-19, in addition to the local standard of care, AstraZeneca said.
Patients in the trial also had a medical history of hypertension, cardiovascular disease and heart failure, type-2 diabetes or chronic kidney disease.
The trial did not achieve statistical significance, with regard to the main goals of prevention and recovery at 30 days. However, AstraZeneca said the safety and tolerability profile makes sure that it is consistent with the medicine’s established safety profile.